Composition based on deuterium-depleted water

Abstract

A composition comprising a deuterium-depleted water (DDW) solution. The DDW solution may comprise an expression-enhancer of Aquaporin-3 comprising Acetyl Hexapeptide- 37, a chelating agent comprising ethylenediaminetetraacetic acid disodium, a humectant glycerin, a stimulator of glycosaminoglycan production comprising Disodium Acetyl Glucosamine Phosphate, and a hyaluronidase inhibitor comprising Rosmarinyl Glucoside.

Description

COMPOSITION BASED ON DEUTERIUM-DEPLETED WATERCROSS-REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of priority from Iran Patent Application Ser. No. 140150140003004931, filed on September 28, 2022, entitled “A base liquid composition for topical products based on Deuterium-Depleted Water with improved water penetration and retention in skin” which is incorporated herein by reference in its entirety.TECHNICAL FIELD

[0002] The present disclosure is generally related to an exemplary composition comprising Deuterium-Depleted Water (DDW) for preparing an exemplary topical formulation in pharmaceutical industries.BACKGROUND

[0003] Skin serves as body's first line of defenses from the external world. Consequently, its role in response to various stimuli, such as sunshine, germs, or physical trauma is to protect and shield body by forming an impermeable physical and water barrier. Common signs of aging in skin appearance include increased dryness, discoloration, unevenness, and wrinkles (rhythides), fine lines, age spots, and sagginess that gives a lifeless and lackluster look to skin. Wrinkles and discoloration are the primary indicators of skin ageing, and these are controlled by a range of internal (genetic, hormone) and external (such as UV rays, heat, smoking, and pollution) factors. Singlet oxygen is an excited state of molecular oxygen generated by UV radiation and may be associated with the damage of skin cells. Different formulations were developed to reduce adverse effects of singlet oxygen but there are some issues to prepare this formulation such as unstable formulation or complicated procedure to prepare formulation. Moreover, these formulations may not be enough effectiveto reduce adverse effects of singlet oxygen on skin cells. Therefore, there is need to develop a water-based formulation comprising a composition that may deactivate singlet oxygen without creating harmful byproducts.SUMMARY

[0004] This summary is intended to provide an overview of the subject matter of the present disclosure, and is not intended to identify essential elements or key elements of the subject matter, nor is it intended to be used to determine the scope of the claimed implementations. Its sole purpose is to present some concepts of one or more exemplary aspects in a simplified form as a prelude to the more detailed description that is presented later. The proper scope of the present disclosure may be ascertained from the claims set forth below in view of the detailed description below and the drawings.

[0005] One or more exemplary embodiments describe an exemplary composition for preparing topical formulations. In an exemplary embodiment, an exemplary composition may comprise an exemplary Deuterium-Depleted Water (DDW) solution. In an exemplary embodiment, an exemplary DDW solution may have an exemplary atomic ratio (deuterium: hydrogen) between 89xl0’6to IxlO-6. In an exemplary embodiment, an exemplary DDW solution may consist of an exemplary expression-enhancer of Aquaporin-3 comprising Acetyl Hexapeptide-37 with an exemplary final concentration between 0.001% (w / w) and 0.0015% (w / w), an exemplary chelating agent with an exemplary final concentration between 0.05% (w / w) and 0.15% (w / w), an exemplary humectant with an exemplary final concentration between 1% (w / w) and 4% (w / w), an exemplary stimulator of glycosaminoglycan production comprising Disodium Acetyl Glucosamine Phosphate with an exemplary final concentration between 0.01% (w / w) and 0.25% (w / w), and an exemplary hyaluronidase inhibitor comprising Rosmarinyl Glucoside with an exemplary final concentration between 0.004% (w / w) and 0.04% (w / w).

[0006] In an exemplary embodiment, an exemplary chelating agent may comprise an exemplary salt of ethylenediaminetetraacetic acid, an exemplary salt of methylglycinediacetic acid, and an exemplary salt of ethylenediamine-N,N'-disuccinic acid. In an exemplary embodiment, an exemplary chelating agent may comprise an exemplary salt of ethylenediaminetetraacetic acid comprising ethylenediaminetetraacetic acid disodium with an exemplary concentration of 0.1% (w / w). In an exemplary embodiment, an exemplary humectant may comprise glycerin with an exemplary concentration of 1.2% (w / w).

[0007] In an exemplary embodiment, an exemplary composition may be an exemplary topical composition. In an exemplary embodiment, an exemplary composition may be prepared in an exemplary topical form of serum, cream, gel, mist, spray, lotion, cream-gel, mask, shampoo, fluid, toner, tonic, roll-on, stick, paste, balm, tint, foam, butter, or mouse.

[0008] This Summary may introduce a number of concepts in a simplified format; the concepts are further disclosed within the “Detailed Description” section. This Summary is not intended to configure essential / key features of the claimed subject matter, nor is intended to limit the scope of the claimed subject matter.BRIEF DESCRIPTION OF THE DRAWINGS

[0009] The novel features which are believed to be characteristic of the present disclosure, as to its structure, organization, use and method of operation, together with further objectives and advantages thereof, will be better understood from the following drawings in which an exemplary embodiment will now be illustrated by way of example. It is expressly understood, however, that the drawings are for the purpose of illustration and description only and are not intended as a definition of the limits of the present disclosure. Exemplary embodiments will now be described by way of example in association with the accompanying drawings in which:

[0010] FIG. 1 illustrates an exemplary flowchart of an exemplary method for preparing an exemplary composition, consistent with one or more exemplary embodiments of the present disclosure.DETAILED DESCRIPTION

[0011] In the following detailed description, numerous specific details are set forth by way of examples to provide a thorough understanding of the relevant teachings related to the exemplary embodiments. However, it should be apparent that the present teachings may be practiced without such details. In other instances, well known methods, procedures, components, and / or circuitry have been described at a relatively high-level, without detail, in order to avoid unnecessarily obscuring aspects of the present teachings.

[0012] The following detailed description is presented to enable a person skilled in the art to make and use the methods and devices disclosed in one or more exemplary embodiments of the present disclosure. For purposes of explanation, specific nomenclature is set forth to provide a thorough understanding of the present disclosure. However, it will be apparent to one skilled in the art that these specific details are not required to practice the disclosed exemplary embodiments. Descriptions of specific exemplary embodiments are provided only as representative examples. Various modifications to the exemplary implementations will be plain to one skilled in the art, and the general principles defined herein may be applied to other implementations and applications without departing from the scope of the present disclosure. The present disclosure is not intended to be limited to the implementations shown, but is to be accorded the widest possible scope consistent with the principles and features disclosed herein.

[0013] Disclosed herein is an exemplary composition for preparing an exemplary topical formulation that may be used in an exemplary pharmaceutical product. An exemplary composition may comprise an exemplary solution of Deuterium-Depleted Water (DDW). Inan exemplary embodiment, an exemplary DDW solution may consist of an exemplary expression-enhancer of Aquaporin-3, an exemplary chelating agent, an exemplary humectant , an exemplary stimulator of glycosaminoglycan production, and an exemplary hyaluronidase inhibitor.

[0014] Typical effects of aging on skin may include dryness, discoloration, unevenness, wrinkles (rhytids), fine lines, age spots, and sagginess appearance. Wrinkles and discoloration are the primary indicators of skin ageing, and these are controlled by a range of internal (genetic, hormone) and external (such as UV rays, heat, smoking, and pollution) factors. One product of UV radiation is singlet oxygen. Singlet oxygen are widely known as mediators of UV photodamage to skin by photosensitization of endogenous (inherent) non- DNA chromophores of skin. Photosensitization occurs as a consequence of photon absorption by endogenous non-DNA chromophores or "Endogenous UVA-photosensitizers" such as Porphyrins in the skin. In this mechanism, so-called photosensitizer, absorbs the UVA rays and the photoexcited state of photosensitizer may be created. This photoexcited photosensitizer may react with molecular oxygen and generate reactive oxygen species such as superoxide radical anion or singlet oxygen which are completely harmful for skin. Hopefully, skin has enzymes for deactivating superoxide radical anion (superoxide dismutase) but, singlet oxygen may harm this enzyme too. Therefore, deactivating singlet oxygen has to be considered as an object for pharmaceutical industries in a topical product to keep skin healthy. Electronic- vibrational deactivation is a mechanism which may deactivate the singlet oxygen. In this mechanism, singlet oxygen collides with a collision partner (another chemical such as solvent) and the electronic excitation energy of singlet oxygen transfers into vibrational energy of terminal bonds of a deactivating collision partner. This non-radiative deactivation method is safe and has no new active chemicals generated after collision. This deactivation may happen for collision partners with terminal O-H bonds fasterthan 0-D bonds; so, electronic-vibrational deactivation of singlet oxygen is favorable forH2O in comparison to D2O. Based on this explanation, reducing the deuterium content (as D2O) of the water used in formulations of the topical product may be a new method to reduce lifetime of the UVA-generated singlet oxygen which leads to decreased photodamage of the skin. Therefore, Using DDW alone may result in attaining advantages like reducing adverse effects of singlet oxygen on skin, however, it is advisable to increase penetration and retention of DDW in skin by adding exemplary chemical compounds to DDW as described in one or more exemplary embodiments.

[0015] In an exemplary embodiment, an exemplary composition may comprise an exemplary solution of DDW with an exemplary atomic ratio (deuterium: hydrogen) between lxl0~6and 89xl0~6. In an exemplary embodiment, an exemplary chelating agent may be selected from the group consisting of an exemplary salt of ethylenediaminetetraacetic acid, an exemplary salt of methylglycinediacetic acid, and an exemplary salt of ethylenediamine - N,N'-disuccinic acid. In an exemplary embodiment, an exemplary salt of ethylenediaminetetraacetic acid may include an exemplary tetrasodium salt of ethylenediaminetetraacetic acid, and an exemplary Disodium salt of ethylenediaminetetraacetic acid. In an exemplary embodiment, an exemplary salt of methylglycinediacetic acid may include an exemplary trisodium salt of methylglycinediacetic acid. In an exemplary embodiment, an exemplary salt of ethylenediamine-N,N'-disuccinic acid may include Trisodium Ethylenediamine Disuccinate.

[0016] In an exemplary embodiment, an exemplary expression-enhancer of Aquaporin- 3 may be selected from the group consisting of madecassoside, glyceryl glucoside, hydrolyzed beta-glucan, acetyl hexapeptide-37, xylitylglucoside, anhydroxylitol, xylitol, stemextract of “Opuntia Ficus indica”, N-acetylglutaminoyl-S-farnesyl-L-cysteine, and cannabidiol.

[0017] In an exemplary embodiment, an exemplary stimulator of glycosaminoglycan production may be selected from the group consisting of Tetrapeptide-21, an exemplary seed extract of “Lin um usitatissimum” (Linseed), an exemplary extract of hydrolyzed Linseed, an exemplary leaf extract of “Nephelium Lappaceum” , an exemplary leaf extract of “Manilkara idullinervis”, Sodium Carrageenan, an exemplary extract of “Undaria pinnalifida". Saccharide isomerate, an exemplary root extract of “Cichorium Inlybus" (Chicory), Disodium Acetyl Glucosamine Phosphate, an exemplary extract of Yeast, an exemplary leaf extract of “Ocimum Sanctum”, an exemplary extract of “Pelvetia Canaliculata” , an exemplary extract of “Echinacea Purpurea”, Beta-Glucan, Palmitoyl Tripeptide -38, an exemplary extract of “Meristotheca Dakarensis” , an exemplary extract of “Jania Rubens”, hydrolyzed Hyaluronic Acid, an exemplary extract of “Corallina Officinalis” , an exemplary extract of “Himanthalia Elongata”, an exemplary extract of “Fucus Vesiculosus” ,and an exemplary extract of “Saccharomyces Cerevisiae” .

[0018] In an exemplary embodiment, an exemplary hyaluronidase inhibitor may be selected from the group consisting of an exemplary extract of hydrolyzed Linseed, an exemplary fruit extract of “Caesalpinia Spinosa”, an exemplary extract of “Helichrysum Italicum”, an exemplary extract of “Undaria Pinnatifida” , Rosmarinyl Glucoside, an exemplary leaf / stem extract of “Hedera Helix (Ivy)”, an exemplary extract of “Halidrys Siliquosa”, an exemplary extract of “Meristotheca Dakarensis” , an exemplary extract of "Jania Rubens”, and an exemplary extract of “ Centaurium Erythraea” .

[0019] In an exemplary embodiment, an exemplary humectant may be selected from the group consisting of sodium pyrrolidone carboxylic acid, tetrapeptide-21, an exemplary (Linseed) seed extract of “Linum usitatissimum”, an exemplary extract of hydrolyzed linseed,an exemplary leaf extract of “Nephelium Lappaceum". an exemplary extract of “ManilkaraMullinervis '. beta-glucan, sodium carrageenan, an exemplary extract of “Undaria pinnalifida", saccharide isomerate, an exemplary extract of hydrolyzed yeast, cetyl hydroxyethylcellulose, polyglucuronic acid, an exemplary root extract of “Cichorium Intybus (Chicory)", an exemplary seed gum of “Tamarindus Indica", yeast polysaccharides, an exemplary extract of “Porphyridium Cruenlum", an exemplary seed polysaccharide of "1'amarindus Indica”, Disodium Acetyl Glucosamine Phosphate, “ pseudoalter omonas exopolysaccharides '. an exemplary stem extract of "Opuntia Ficus- Indica", inulin, yeast extract, an exemplary leaf extract of “Ocimum Sanctum”, an exemplary extract of “Pelvetia Canaliculata” , an exemplary extract of “Echinacea Purpurea”, hydroxypropyl cyclodextrin, palmitoyl tripeptide -38, palmitoyl tripeptide-5, an exemplary extract of “Meristotheca Dakarensis” , an exemplary extract of “Jania Rubens”, Silanetriol, an exemplary extract of “Undaria Pinnatifida” , an exemplary extract of “Corallina Officinalis” , an exemplary extract of “Himanthalia Elongata”, an exemplary extract of “Fucus Vesiculosus” , and an exemplary extract of “Saccharomyces Cerevisiae” .

[0020] In an exemplary embodiment, an exemplary composition may consist of an exemplary DDW solution. In an exemplary embodiment, an exemplary DDW solution may consist of ethylenediaminetetraacetic acid disodium, Acetyl Hexapep tide-37, Disodium Acetyl Glucosamine, Rosmarinyl Glucoside, and glycerin. In an exemplary embodiment, an exemplary composition may consist of an exemplary solution of DDW comprising ethylenediaminetetraacetic acid disodium with an exemplary final concentration between 0.05% (w / w) and 0.15% (w / w), Acetyl Hexapeptide-37 with an exemplary final concentration between 0.001% (w / w) and 0.0015% (w / w), Disodium Acetyl Glucosamine Phosphate with an exemplary final concentration between 0.01% (w / w) and 0.25% (w / w), Rosmarinyl Glucoside with an exemplary final concentration between 0.004% (w / w) and0.04% (w / w), and glycerin with an exemplary final concentration between 1% (w / w) and 4% (w / w).

[0021] Referring to the figures, FIG. 1 illustrates an exemplary flowchart of exemplary method 100 for preparing an exemplary composition, consistent with one or more exemplary embodiments of the present disclosure. In an exemplary embodiment, exemplary method 100 may include: forming an exemplary liquid mixture by adding an exemplary chelating agent to an exemplary DDW (step 102); mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes (step 104); adding an exemplary DDW solution of an exemplary expression enhancer of Aquaporin-3 to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes (step 106); adding an exemplary DDW solution of an exemplary stimulator of glycosaminoglycan production to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes (step 108); adding an exemplary DDW solution of an exemplary hyaluronidase inhibitor to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes (step 110); adding an exemplary humectant to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 10 and 15 minutes (step 112).

[0022] In further detail with respect to step 102, step 102 may include forming an exemplary liquid mixture by adding an exemplary chelating agent to an exemplary DDW. In an exemplary embodiment, an exemplary DDW may have an exemplary atomic ratio (deuterium: hydrogen) between 89xl0-6to IxlO-6. In an exemplary embodiment, anexemplary chelating agent may be weighed by an exemplary laboratory scale and then may be added by spatula to an exemplary DDW in an exemplary laboratory container including, but not limited to, beakers, tins, flasks, bottles, buckets, basins, bowls, vials, tubes, barrels, cannisters, etc. In an exemplary embodiment, the exemplary laboratory container comprising liquid mixture at step 102 may be added to an exemplary stainless-steel storage. “Chelating agent” may refer to a chemical compound that may bind to metal ions and remove them. The exemplary chelating agent may bind to exemplary metal ions and may remove these ions from skin. Therefore, water channels of cell (Aquaporin-3) may be free from metal ions. Therefore; water and glycerin may be easily passed from these channels.

[0023] In further detail with respect to step 104, step 104 may include mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes. In an exemplary embodiment, the exemplary liquid mixture at step 104 may be mixed in the exemplary stainless- steel storage using an exemplary dispersion blade.

[0024] In further detail with respect to step 106, step 106 may include adding an exemplary DDW solution of an exemplary expression enhancer of Aquaporin-3 to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes. In an exemplary embodiment, an exemplary DDW solution of an exemplary expression enhancer of Aquaporin-3 may be prepared by adding an exemplary powder of Acetyl Hexapeptide- 37 to DDW with an exemplary concentration of 0.1% (w / w). In an exemplary embodiment, an exemplary powder of Acetyl Hexapeptide-37 may be weighed by an exemplary laboratory scale and then may be added by spatula to an exemplary DDW in an exemplary laboratory container including, but not limited to, beakers, tins, flasks, bottles, buckets, basins, bowls, vials, tubes, barrels, cannisters, etc. In other words, an exemplaryDDW solution of an exemplary expression enhancer of Aquaporin-3 may include an exemplary solution of Acetyl Hexapeptide-37 with an exemplary concentration of 0.1% (w / w). In an exemplary embodiment, an exemplary DDW solution of an exemplary expression enhancer of Aquaporin-3 in an exemplary laboratory container may be added to the exemplary stainless-steel storage containing the liquid mixture of step 104. In an exemplary embodiment, the exemplary liquid mixture at step 106 may be mixed in the exemplary stainless- steel storage using an exemplary dispersion blade. “Aquaporin” may refer to a group of tiny membrane- spanning proteins that are expressed at plasma membranes in a variety of cell types that are essential in fluid transport. “Aquaporin-3” may refer to a membrane transmitter of water and glycerol which may be expressed in plasma membranes of cells located in different layers of epidermis and dermis in normal skin.

[0025] In further detail with respect to step 108, step 108 may include adding an exemplary DDW solution of an exemplary stimulator of glycosaminoglycan production to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes. In an exemplary embodiment, an exemplary DDW solution of an exemplary stimulator of glycosaminoglycan production may be prepared by adding an exemplary powder of Disodium Acetyl Glucosamine Phosphate to an exemplary DDW with an exemplary concentration of 5% (w / w). In an exemplary embodiment, an exemplary powder of Disodium Acetyl Glucosamine Phosphate may be weighed by an exemplary laboratory scale and then may be added by spatula to an exemplary DDW in an exemplary laboratory container including, but not limited to, beakers, tins, flasks, bottles, buckets, basins, bowls, vials, tubes, barrels, cannisters, etc. In other words, an exemplary DDW solution of an exemplary stimulator of glycosaminoglycan production may include an exemplary solution of Disodium Acetyl Glucosamine Phosphate with an exemplary concentration of 5% (w / w). Inan exemplary embodiment, an exemplary DDW solution of an exemplary stimulator of glycosaminoglycan production in an exemplary laboratory container may be added to the exemplary stainless-steel storage containing the liquid mixture of step 106. In an exemplary embodiment, the exemplary liquid mixture at step 108 may be mixed in the exemplary stainless- steel storage of using an exemplary dispersion blade. “Glycosaminoglycan” may refer to a group of mucopolysaccharides which are polysaccharide compounds. Glycosaminoglycans may comprise repeating disaccharide units which are present in every mammalian tissue. The functions of these compounds are widespread within the body and determined by their molecular structure. In skin, the function of glycosaminoglycan may be limited to cell hydration and structural scaffolding. Hyaluronic acid is one of the glycosaminoglycan which may be present in skin. Hyaluronic acid is essential for preserving the structural and functional integrity of the skin, for preventing wrinkles, and for keeping the skin's smooth, young, and moisturized appearance.

[0026] In further detail with respect to step 110, step 110 may include adding an exemplary DDW solution of an exemplary hyaluronidase inhibitor to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 2 and 5 minutes. In an exemplary embodiment, an exemplary DDW solution of an exemplary hyaluronidase inhibitor may be prepared by adding an exemplary powder of Rosmarinyl Glucoside to DDW with an exemplary concentration of 2% (w / w). In an exemplary embodiment, an exemplary powder of Rosmarinyl Glucoside may be weighed by an exemplary laboratory scale and then may be added by spatula to an exemplary DDW in an exemplary laboratory container including, but not limited to, beakers, tins, flasks, bottles, buckets, basins, bowls, vials, tubes, barrels, cannisters, etc. In other words, an exemplary DDW solution of an exemplary hyaluronidase inhibitor may include an exemplary solution of Rosmarinyl Glucoside with an exemplaryconcentration of 2% (w / w). In an exemplary embodiment, an exemplary DDW solution of an exemplary hyaluronidase inhibitor in an exemplary laboratory container may be added to the exemplary stainless-steel storage containing the liquid mixture of step 108. In an exemplary embodiment, the exemplary liquid mixture at step 110 may be mixed in the exemplary stainless- steel storage using an exemplary dispersion blade. “Hyaluronidase” may refer to a dermal enzyme which may depolymerize hyaluronic acid causing dryness and skin wrinkles. It also reduces the viscosity of bodily fluids and enhances the permeability of connective tissues. “Hyaluronidase inhibitor” may refer to an agent which may inhibit hyaluronidase from acting as a depolymerizer of hyaluronic acid.

[0027] In further detail with respect to step 112, step 112 may include adding an exemplary humectant to the exemplary liquid mixture and mixing the exemplary liquid mixture at an exemplary temperature between 20 °C and 25 °C for an exemplary time duration between 10 and 15 minutes. In an exemplary embodiment, an exemplary humectant may be glycerin. In an exemplary embodiment, an exemplary humectant may be weighed by an exemplary laboratory scale and then may be transferred to an exemplary beaker. In an exemplary embodiment, an exemplary humectant in an exemplary beaker may be added to the exemplary stainless-steel storage containing the exemplary liquid mixture of step 110. In an exemplary embodiment, the exemplary liquid mixture at step 112 may be mixed in the exemplary stainless- steel storage using an exemplary dispersion blade.

[0028] In an exemplary embodiment, an exemplary composition may be an exemplary topical composition. In an exemplary embodiment, an exemplary topical composition may be prepared as an exemplary dosage form of topical formulation including, but not limited to, serum, cream, gel, mist, spray, lotion, cream-gel, mask, shampoo, fluid, toner, tonic, roll-on, stick, paste, balm, tint, foam, butter, or mouses, etc.EXAMPLES

[0029] Hereinafter, one or more exemplary embodiments will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples may be for illustrative purposes only and are not to be interpreted to limit the scope of the present disclosure.Example 1: Preparation of an exemplary composition

[0030] In this example a preparation procedure of the exemplary composition was described. At first, a deuterium-depleted Water (DDW) solution of Acetyl Hexapeptide-37 (0.1% (w / w)), Disodium Acetyl Glucosamine Phosphate (5% (w / w)), Rosmarinyl Glucoside (2% (w / w)) was prepared.

[0031] Table 1 below shows an exemplary concentration of ingredients applied to produce the exemplary composition, consistent with one or more exemplary embodiments of the present disclosure. An exemplary liquid mixture was formed by adding ethylenediaminetetraacetic acid disodium with a concentration according to Table 1 and was mixed at the temperature between 20 °C and 25 °C for the time duration of 3 minutes. At next stage, the DDW solution of acetyl hexapeptide-37 with a concentration according to Table 1 was added to the liquid mixture and was mixed at the temperature between 20 °C and 25 °C for the time duration of 3 minutes. Next, the DDW solution of Disodium Acetyl Glucosamine Phosphate with a concentration according to Table 1 was added to the liquid mixture and was mixed at the temperature between 20 °C and 25 °C for the time duration of 3 minutes. Then, the DDW solution of Rosmarinyl Glucoside with a concentration according to Table 1 was added to the liquid mixture and was mixed at the temperature between 20 °C and 25 °C for the time duration of 3 minutes. Finally, glycerin with a concentration according to Table 1 was added to the liquid mixture and was mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes.Table 1:Concentration of ingredients applied to produce the exemplary composition, consistent with one or more exemplary embodiments of the present disclosure.Example 2: Preparation of an exemplary anti-wrinkle serum

[0032] In this example, a preparation procedure of the exemplary anti-wrinkle serum was described. Table 2 below shows concentration of ingredients applied to produce the exemplary anti-wrinkle serum, consistent with one or more exemplary embodiments of the present disclosure. At first, the composition according to Example 1 was prepared. Then xanthan gum with a concentration according to Table 2 was added to the exemplary composition and was mixed at the temperature between 20 °C and 25 °C for the time duration between 25 and 30 minutes. At next stage, phytosterol with a concentration according to Table 2 was added to the composition and mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes. Then, Euxyl® PE 9010 and fragrancewith a concentration according to Table 2 was added to the exemplary composition and was mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes. Finally, the DDW was added until the total weight of the composition reached to 100 g.Table 2:Concentration of ingredients applied to produce the exemplary anti-wrinkle serum, consistent with one or more exemplary embodiments of the present disclosure.Example 3: Preparation of an exemplary micellar water

[0033] In this example, a preparation procedure of the exemplary micellar water was described. Table 3 below shows concentration of ingredients applied to produce the exemplary micellar water, consistent with one or more exemplary embodiments of the present disclosure. At first, the composition according to Example 1 was prepared. Then propylene glycol, polysorbate 80, coco-glucoside, PEG- 12 dimethicone, and PEG-6caprylic / capric glycerides with a concentration according to Table 3 were added to the exemplary composition and was mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes. At next stage, phenoxyethanol, fragrance, and citric acid anhydrous with a concentration according to Table 3 was added to the composition and mixed at the temperature between 20 °C and 25 °C for the time duration of 20 minutes. Finally, the DDW was added until the total weight of the composition reached to 100 g.Table 3:Concentration of ingredients applied to produce the exemplary micellar water, consistent with one or more exemplary embodiments of the present disclosure.Example 4: Preparation of an exemplary moisturizing cream

[0034] In this example, a preparation procedure of the exemplary moisturizing cream was described. Table 4 below shows concentration of ingredients applied to produce the exemplary moisturizing cream, consistent with one or more exemplary embodiments of the present disclosure. At first, the composition according to Example 1 was prepared. Then Viscolam® AT 100 P with a concentration according to Table 4 was added to the exemplary composition and was mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes. At next stage, caprylic / capric triglyceride, fragrance, and Euxyl® PE 9010 with a concentration according to Table 4 was added to the composition and mixed at the temperature between 20 °C and 25 °C for the time duration of 20 minutes. Finally, the DDW was added until the total weight of the composition reached to 100 g.Table 4:Concentration of ingredients applied to produce the exemplary moisturizing cream, consistent with one or more exemplary embodiments of the present disclosure.Example 5: Preparation of an exemplary water mist

[0035] In this example, a preparation procedure of the exemplary water mist was described. Table 5 below shows concentration of ingredients applied to produce the exemplary water mist, consistent with one or more exemplary embodiments of the present disclosure. At first, the composition according to Example 5 was prepared. Then phenoxyethanol, fragrance, and citric acid anhydrous with a concentration according to Table 5 was added to the exemplary composition and was mixed at the temperature between 20 °C and 25 °C for the time duration between 10 and 15 minutes. Finally, the DDW was added until the total weight of the composition reached to 100 g.Table 5:Concentration of ingredients applied to produce the exemplary water mist, consistent with one or more exemplary embodiments of the present disclosure.

[0036] While the foregoing has described what are considered to be the best mode and / or other examples, it is understood that various modifications may be made therein and that the subject matter disclosed herein may be implemented in various forms and examples, and that the teachings may be applied in numerous applications, only some of which have been described herein. It is intended by the following claims to claim any and all applications, modifications and variations that fall within the true scope of the present teachings.

[0037] Unless otherwise stated, all measurements, values, ratings, positions, magnitudes, sizes, and other specifications that are set forth in this specification, including in the claims that follow, are approximate, not exact. They are intended to have a reasonable range that is consistent with the functions to which they relate and with what is customary in the art to which they pertain.

[0038] The scope of protection is limited solely by the claims that now follow. That scope is intended and should be interpreted to be as broad as is consistent with the ordinary meaning of the language that is used in the claims when interpreted in light of this specification and the prosecution history that follows and to encompass all structural and functional equivalents. Notwithstanding, none of the claims are intended to embrace subject matter that fails to satisfy the requirement of Sections 101, 102, or 103 of the Patent Act, nor should they be interpreted in such a way. Any unintended embracement of such subject matter is hereby disclaimed.

[0039] Except as stated immediately above, nothing that has been stated or illustrated is intended or should be interpreted to cause a dedication of any component, step, feature, object, benefit, advantage, or equivalent to the public, regardless of whether it is or is not recited in the claims.

[0040] It will be understood that the terms and expressions used herein have the ordinary meaning as is accorded to such terms and expressions with respect to their corresponding respective areas of inquiry and study except where specific meanings have otherwise been set forth herein. Relational terms such as first and second and the like may be used solely to distinguish one entity or action from another without necessarily requiring or implying any actual such relationship or order between such entities or actions. An element proceeded by “a” or “an” does not, without further constraints, preclude the existence of additional identical elements in the process, method, article, or apparatus that comprises the element.

[0041] Unless otherwise stated, all measurements, values, ratings, positions, magnitudes, sizes, and other specifications that are set forth in this specification, are approximate, not exact. They are intended to have a reasonable range that is consistent with the functions to which they relate and with what is customary in the art to which they pertain.

[0042] It will be understood that the terms and expressions used herein have the ordinary meaning as is accorded to such terms and expressions with respect to their corresponding respective areas of inquiry and study, except where specific meanings have otherwise been set forth herein. Relational terms such as “first” and “second” and the like may be used solely to distinguish one entity or action from another without necessarily requiring or implying any actual such relationship or order between such entities or actions.

[0043] The Abstract of the Disclosure is provided to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. In addition, in the foregoing Detailed Description, it may be seen that various features are grouped together in various implementations. This is for purposes of streamlining the disclosure, and is not to be interpreted as reflecting an intention that the claimed implementations require more featuresthan are expressly recited in each claim. Rather, as the following claims reflect, inventive subject matter lies in less than all features of a single disclosed implementation. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separately claimed subject matter.

[0044] While various implementations have been described, the description is intended to be exemplary, rather than limiting and it will be apparent to those of ordinary skill in the art that many more implementations and implementations are possible that are within the scope of the implementations. Although many possible combinations of features are shown in the accompanying figures and discussed in this detailed description, many other combinations of the disclosed features are possible. Any feature of any implementation may be used in combination with or substituted for any other feature or element in any other implementation unless specifically restricted. Therefore, it will be understood that any of the features shown and / or discussed in the present disclosure may be implemented together in any suitable combination. Accordingly, the implementations are not to be restricted except in light of the attached claims and their equivalents. Also, various modifications and changes may be made within the scope of the attached claims.

Claims

What is claimed is:

1. A composition, consisting of: a Deuterium-Depleted Water (DDW) solution in which an atomic ratio (deuterium: hydrogen) of DDW is between 89xl0’6and IxlO-6, the DDW solution consisting of: an expression-enhancer of Aquaporin-3 comprising Acetyl Hexapeptide- 37 with a final concentration between 0.001% (w / w) and 0.0015% (w / w); a chelating agent with a final concentration between 0.05% (w / w) and 0.15% (w / w); a humectant with a final concentration between 1% (w / w) and 4% (w / w); a stimulator of glycosaminoglycan production comprising Disodium Acetyl Glucosamine Phosphate with a final concentration between 0.01% (w / w) and 0.25% (w / w); and a hyaluronidase inhibitor comprising Rosmarinyl Glucoside with a final concentration between 0.004% (w / w) and 0.04% (w / w).

2. The composition of claim 1, wherein the chelating agent comprises a salt of ethylenediaminetetraacetic acid, a salt of methylglycinediacetic acid, and a salt of ethylenediamine-N,N'-disuccinic acid.

3. The composition of claim 2, wherein the chelating agent comprises ethylenediaminetetraacetic acid disodium with a final concentration of 0.1% (w / w).

4. The composition of claim 1, wherein the humectant comprises glycerin with a final concentration of 1.2% (w / w).

5. The composition of claim 1, wherein the composition is a topical composition.

6. The composition of claim 1, wherein the composition is in a topical form selected from the group consisting of serum, cream, gel, mist, spray, lotion, cream-gel, mask, shampoo, fluid, toner, tonic, roll-on, stick, paste, balm, tint, foam, butter, or mouse.

7. A composition, consisting of: a Deuterium-Depleted Water (DDW) solution consisting of: an expression-enhancer of Aquaporin-3 comprising Acetyl Hexapeptide-37; a chelating agent; a humectant; a stimulator of glycosaminoglycan production comprising Disodium Acetyl Glucosamine Phosphate; and a hyaluronidase inhibitor comprising Rosmarinyl Glucoside.

8. The composition of claim 7, wherein an atomic ratio (deuterium: hydrogen) of DDW is between 89xl0’6and IxlO-6.

9. The composition of claim 7, wherein the Acetyl Hexapeptide-37 has a concentration between 0.001% and 0.0015 % (w / w).

10. The composition of claim 7, wherein the Disodium Acetyl Glucosamine Phosphate has a concentration between 0.01% and 0.

25. % (w / w).

11. The composition of claim 7, wherein the Rosmarinyl Glucoside has a concentration between 0.004% and 0.

04. % (w / w).

12. The composition of claim 7, wherein the chelating agent comprises a salt of ethylenediaminetetraacetic acid, a salt of methylglycinediacetic acid, and a salt of ethylenediamine-N,N'-disuccinic acid.

13. The composition of claim 7, wherein the chelating agent comprises ethylenediaminetetraacetic acid disodium with a concentration of 0.1% (w / w).

14. The composition of claim 7, wherein the humectant comprises glycerin with a concentration of 1.2% (w / w).

15. The composition of claim 7, wherein the composition is a topical composition.

16. The composition of claim 7, wherein the composition is in a topical form selected from the group consisting of serum, cream, gel, mist, spray, lotion, cream-gel, mask, shampoo, fluid, toner, tonic, roll-on, stick, paste, balm, tint, foam, butter, or mouse.

Images